Product Code: GVR-4-68040-092-1
U.S. Ketamine Clinics Market Growth & Trends
The U.S. ketamine clinics market size is expected to reach USD 6.9 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 10.63% from 2023 to 2030. The market is experiencing significant growth, driven by factors such as increasing mental health awareness, the ongoing opioid crisis, and expanding number of ketamine clinics across the U.S. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), about 13% of young adults aged 18 to 25 have mental or substance use problems. Additionally, 1 in 4 Americans have a mental illness, and 1 out of 3 have a substance use disorder. The increasing number of people with addictions and mental health disorders is contributing to the growth.
The COVID-19 pandemic had a significant impact on online ketamine therapy clinics. While onsite providers faced challenges such as lockdowns, disruptions in the supply chain, and people's fear of contracting the virus. Consequently, many individuals avoided visiting clinics or hospitals. However, the pandemic led to a surge in mental health issues in the U.S. as people faced increased stress, anxiety, and depression. Disruptions in daily routines, social isolation, and increased stress related to finances and employment contributed to a rise in mental health disorders. According to Mental Health America (MHA), 35% of the people screened in the U.S. from January to September 2020 reported having depression, while 20% reported experiencing anxiety.
Key players in the U.S. ketamine clinics industry are implementing various strategies such as mergers & acquisitions, partnerships, expansions, and launching new services to expand their market presence. These efforts are expected to contribute to the market's growth. For instance, in April 2023, Mindbloom, Inc., a ketamine therapy provider, partnered with SHIFT, a tech-based management consulting company. As part of this partnership, SHIFT employees will now have the opportunity to receive at-home ketamine therapy from Mindbloom at a reduced cost compared to the regular price. This initiative aims to provide a valuable benefit to SHIFT employees.
U.S. Ketamine Clinics Market Report Highlights
- Based on the treatment, the depression segment held the largest market share in 2022 owing to the growing number of American adults burdened with severe major depression
- The anxiety segment is anticipated to witness the fastest growth over the forecast period. Anxiety disorders are the most widespread mental illness in the U.S. As a result, there is an increased need for treatment and support for anxiety disorders, which is expected to drive the segment's growth
- Based on the therapy, the on-site therapy segment held the largest market share in 2022. Growing acceptance of ketamine therapy for mental health disorder is led to an expansion of ketamine clinics in the U.S., further driving the segment growth
- The growth of the online therapy segment significantly impacted the overall U.S. ketamine clinics industry. With the rise of telehealth and remote healthcare services, the accessibility and convenience of online ketamine therapy have expanded significantly
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Market Definitions
- 1.2. Estimates and Forecast Timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources & Third-Party Perspectives
- 1.4.4. Primary Research
- 1.5. Information Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Data Visualization
- 1.7. Model Details
- 1.8. List of Secondary Sources
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.2. Market Restraint Analysis
- 3.4. Business Environment Analysis
- 3.4.1. PESTLE Analysis
- 3.4.2. Porter's Five Forces Analysis
- 3.5. COVID-19 Impact Analysis
Chapter 4. Treatment Business Analysis
- 4.1. Ketamine Clinics Market: Treatment Movement Analysis & Market Share, 2022 & 2030
- 4.2. Depression
- 4.2.1. U.S. Depression Market, 2018 - 2030 (USD Million)
- 4.3. Anxiety
- 4.3.1. U.S. Anxiety Market, 2018 - 2030 (USD Million)
- 4.4. PTSD
- 4.4.1. U.S. PTSD Market, 2018 - 2030 (USD Million)
- 4.5. Others
- 4.5.1. U.S. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Therapy Business Analysis
- 5.1. Ketamine Clinics Market: Therapy Movement Analysis & Market Share, 2022 & 2030
- 5.2. On-Site Therapy
- 5.2.1. U.S. On-Site Therapy Market, 2018 - 2030 (USD Million)
- 5.3. Online Therapy
- 5.3.1. U.S. Online Therapy Market, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Company Categorization
- 6.2. Strategy Mapping
- 6.2.1. Expansion
- 6.2.2. Acquisition
- 6.2.3. Collaborations
- 6.2.4. New Product Launches
- 6.2.5. Others
- 6.3. Company Profiles/Listing
- 6.3.1. NY Ketamine Infusions
- 6.3.1.1. Overview
- 6.3.1.2. Financial Performance
- 6.3.1.3. Product Benchmarking
- 6.3.1.4. Strategic Initiatives
- 6.3.2. Field Trip Health and Wellness Ltd.
- 6.3.2.1. Overview
- 6.3.2.2. Financial Performance
- 6.3.2.3. Product Benchmarking
- 6.3.2.4. Strategic Initiatives
- 6.3.3. Ketamine Clinics Los Angeles
- 6.3.3.1. Overview
- 6.3.3.2. Financial Performance
- 6.3.3.3. Product Benchmarking
- 6.3.3.4. Strategic Initiatives
- 6.3.4. Klarity Clinic
- 6.3.4.1. Overview
- 6.3.4.2. Financial Performance
- 6.3.4.3. Product Benchmarking
- 6.3.4.4. Strategic Initiatives
- 6.3.5. Vitalitas Denver Ketamine Centers
- 6.3.5.1. Overview
- 6.3.5.2. Financial Performance
- 6.3.5.3. Product Benchmarking
- 6.3.5.4. Strategic Initiatives
- 6.3.6. Mindbloom, Inc
- 6.3.6.1. Overview
- 6.3.6.2. Financial Performance
- 6.3.6.3. Product Benchmarking
- 6.3.6.4. Strategic Initiatives
- 6.3.7. Nue Life Health
- 6.3.7.1. Overview
- 6.3.7.2. Financial Performance
- 6.3.7.3. Product Benchmarking
- 6.3.7.4. Strategic Initiatives
- 6.3.8. Better U, LLC
- 6.3.8.1. Overview
- 6.3.8.2. Financial Performance
- 6.3.8.3. Product Benchmarking
- 6.3.8.4. Strategic Initiatives
- 6.3.9. Innerwell
- 6.3.9.1. Overview
- 6.3.9.2. Financial Performance
- 6.3.9.3. Product Benchmarking
- 6.3.9.4. Strategic Initiatives
- 6.3.10. Klarisana
- 6.3.10.1. Overview
- 6.3.10.2. Financial Performance
- 6.3.10.3. Product Benchmarking
- 6.3.10.4. Strategic Initiatives
Chapter 7. Recommendations/Key Market Insights